戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d receptor agonists (SCRAs), and other novel synthetic drugs.
2 lly offers a safe and natural alternative to synthetic drugs.
3 ompared to more expensive growth factors and synthetic drugs.
4 tides and inform the design of peptide-based synthetic drugs.
5 ing strategy for assessing hepatotoxicity of synthetic drugs.
6 resents the first neoglycorandomization of a synthetic drug and expands our understanding of the impa
7 istinct from areas addressed by conventional synthetic drugs and drug-like molecules.
8 e collection of organic molecules (including synthetic drugs and natural products).
9 e chemical behaviour of natural ingredients, synthetic drugs and other related compounds complexed us
10 such as those involving the substructures of synthetic drugs and protein domains, is important in fra
11 ity sensor that recognizes a wide variety of synthetic drugs and xenobiotic agents.
12  consequence, alcohols are rarely present in synthetic drugs but predominantly found in therapeutics
13 h the broad applicability and versatility of synthetic drug delivery particles.
14                                           No synthetic drug delivery system composed of biodegradable
15 ysiological barriers that are impermeable to synthetic drug-delivery vehicles.
16 ducts offer an attractive option compared to synthetic drugs due to their well-established safety pro
17 this class and of comparable activity to the synthetic drug fludarubin.
18                        As the development of synthetic drugs for the prevention of stroke has proven
19 of these processes by endogenous ligands and synthetic drugs is a poorly understood area of GPCR sign
20 portant dimension of the risk represented by synthetic drugs is the fact that they are increasingly p
21 ation of the opioid receptors by opiates and synthetic drugs leads to central and peripheral biologic
22 erived from two sources-natural products and synthetic drug-like compounds.
23                        Finally, we show that synthetic drug-like derivatives of 24(S)-HC, which poten
24                                              Synthetic drug-like molecules that directly modulate the
25 imate protection from filovirus disease by a synthetic drug-like small molecule.
26                                   Studies on synthetic drug-like small-molecule macrocycles are limit
27  first example of clinical resistance to the synthetic drug linezolid which involves a natural resist
28  of functions of both endogenous ligands and synthetic drug molecules.
29 rticularly for fentanyl, an extremely potent synthetic drug of abuse and a main perpetrator in the op
30 ened the scope of populations susceptible to synthetic drug overdose in North America (eg, among adol
31 A, (R)-calycotomine and (R)-colchietine, the synthetic drug (R)-almorexant and the (S)-enantiomer of
32                                            A synthetic drug, T113242, activates low-density lipoprote
33             This model may aid the design of synthetic drugs targeted at this transcriptional regulat
34                                         From synthetic drugs to biodegradable plastics to the origin
35 s, a variety of complex natural products and synthetic drugs were glucosylated or xylosylated by Sv01